Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria
ABSTRACT A novel type of antibacterial screening method, a target mechanism-based whole-cell screening method, was developed to combine the advantages of target mechanism- and whole-cell-based approaches. A mycobacterial reporter strain with a synthetic phenotype for caseinolytic protease (ClpP1P2)...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2015-07-01
|
| Series: | mBio |
| Online Access: | https://journals.asm.org/doi/10.1128/mBio.00253-15 |
| _version_ | 1818838305064615936 |
|---|---|
| author | Wilfried Moreira Grace J. Y. Ngan Jian Liang Low Anders Poulsen Brian C. S. Chia Melgious J. Y. Ang Amelia Yap Justina Fulwood Umayal Lakshmanan Jolander Lim Audrey Y. T. Khoo Horst Flotow Jeffrey Hill Ravikiran M. Raju Eric J. Rubin Thomas Dick |
| author_facet | Wilfried Moreira Grace J. Y. Ngan Jian Liang Low Anders Poulsen Brian C. S. Chia Melgious J. Y. Ang Amelia Yap Justina Fulwood Umayal Lakshmanan Jolander Lim Audrey Y. T. Khoo Horst Flotow Jeffrey Hill Ravikiran M. Raju Eric J. Rubin Thomas Dick |
| author_sort | Wilfried Moreira |
| collection | DOAJ |
| description | ABSTRACT A novel type of antibacterial screening method, a target mechanism-based whole-cell screening method, was developed to combine the advantages of target mechanism- and whole-cell-based approaches. A mycobacterial reporter strain with a synthetic phenotype for caseinolytic protease (ClpP1P2) activity was engineered, allowing the detection of inhibitors of this enzyme inside intact bacilli. A high-throughput screening method identified bortezomib, a human 26S proteasome drug, as a potent inhibitor of ClpP1P2 activity and bacterial growth. A battery of secondary assays was employed to demonstrate that bortezomib indeed exerts its antimicrobial activity via inhibition of ClpP1P2: Down- or upmodulation of the intracellular protease level resulted in hyper- or hyposensitivity of the bacteria, the drug showed specific potentiation of translation error-inducing aminoglycosides, ClpP1P2-specific substrate WhiB1 accumulated upon exposure, and growth inhibition potencies of bortezomib derivatives correlated with ClpP1P2 inhibition potencies. Furthermore, molecular modeling showed that the drug can bind to the catalytic sites of ClpP1P2. This work demonstrates the feasibility of target mechanism-based whole-cell screening, provides chemical validation of ClpP1P2 as a target, and identifies a drug in clinical use as a new lead compound for tuberculosis therapy. IMPORTANCE During the last decade, antibacterial drug discovery relied on biochemical assays, rather than whole-cell approaches, to identify molecules that interact with purified target proteins derived by genomics. This approach failed to deliver antibacterial compounds with whole-cell activity, either because of cell permeability issues that medicinal chemistry cannot easily fix or because genomic data of essentiality insufficiently predicted the vulnerability of the target identified. As a consequence, the field largely moved back to a whole-cell approach whose main limitation is its black-box nature, i.e., that it requires trial-and-error chemistry because the cellular target is unknown. We developed a novel type of antibacterial screening method, target mechanism-based whole-cell screening, to combine the advantages of both approaches. We engineered a mycobacterial reporter strain with a synthetic phenotype allowing us to identify inhibitors of the caseinolytic protease (ClpP1P2) inside the cell. This approach identified bortezomib, an anticancer drug, as a specific inhibitor of ClpP1P2. We further confirmed the specific “on-target” activity of bortezomib by independent approaches including, but not limited to, genetic manipulation of the target level (over- and underexpressing strains) and by establishing a dynamic structure-activity relationship between ClpP1P2 and growth inhibition. Identifying an “on-target” compound is critical to optimize the efficacy of the compound without compromising its specificity. This work demonstrates the feasibility of target mechanism-based whole-cell screening methods, validates ClpP1P2 as a druggable target, and delivers a lead compound for tuberculosis therapy. |
| first_indexed | 2024-12-19T03:36:17Z |
| format | Article |
| id | doaj.art-759d7a3e9b8f46bb802568696b32e7c6 |
| institution | Directory Open Access Journal |
| issn | 2150-7511 |
| language | English |
| last_indexed | 2024-12-19T03:36:17Z |
| publishDate | 2015-07-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | mBio |
| spelling | doaj.art-759d7a3e9b8f46bb802568696b32e7c62022-12-21T20:37:22ZengAmerican Society for MicrobiologymBio2150-75112015-07-016310.1128/mBio.00253-15Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in MycobacteriaWilfried Moreira0Grace J. Y. Ngan1Jian Liang Low2Anders Poulsen3Brian C. S. Chia4Melgious J. Y. Ang5Amelia Yap6Justina Fulwood7Umayal Lakshmanan8Jolander Lim9Audrey Y. T. Khoo10Horst Flotow11Jeffrey Hill12Ravikiran M. Raju13Eric J. Rubin14Thomas Dick15Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, SingaporeDepartment of Microbiology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, SingaporeDepartment of Microbiology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeExperimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), SingaporeDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USADepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USADepartment of Microbiology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, SingaporeABSTRACT A novel type of antibacterial screening method, a target mechanism-based whole-cell screening method, was developed to combine the advantages of target mechanism- and whole-cell-based approaches. A mycobacterial reporter strain with a synthetic phenotype for caseinolytic protease (ClpP1P2) activity was engineered, allowing the detection of inhibitors of this enzyme inside intact bacilli. A high-throughput screening method identified bortezomib, a human 26S proteasome drug, as a potent inhibitor of ClpP1P2 activity and bacterial growth. A battery of secondary assays was employed to demonstrate that bortezomib indeed exerts its antimicrobial activity via inhibition of ClpP1P2: Down- or upmodulation of the intracellular protease level resulted in hyper- or hyposensitivity of the bacteria, the drug showed specific potentiation of translation error-inducing aminoglycosides, ClpP1P2-specific substrate WhiB1 accumulated upon exposure, and growth inhibition potencies of bortezomib derivatives correlated with ClpP1P2 inhibition potencies. Furthermore, molecular modeling showed that the drug can bind to the catalytic sites of ClpP1P2. This work demonstrates the feasibility of target mechanism-based whole-cell screening, provides chemical validation of ClpP1P2 as a target, and identifies a drug in clinical use as a new lead compound for tuberculosis therapy. IMPORTANCE During the last decade, antibacterial drug discovery relied on biochemical assays, rather than whole-cell approaches, to identify molecules that interact with purified target proteins derived by genomics. This approach failed to deliver antibacterial compounds with whole-cell activity, either because of cell permeability issues that medicinal chemistry cannot easily fix or because genomic data of essentiality insufficiently predicted the vulnerability of the target identified. As a consequence, the field largely moved back to a whole-cell approach whose main limitation is its black-box nature, i.e., that it requires trial-and-error chemistry because the cellular target is unknown. We developed a novel type of antibacterial screening method, target mechanism-based whole-cell screening, to combine the advantages of both approaches. We engineered a mycobacterial reporter strain with a synthetic phenotype allowing us to identify inhibitors of the caseinolytic protease (ClpP1P2) inside the cell. This approach identified bortezomib, an anticancer drug, as a specific inhibitor of ClpP1P2. We further confirmed the specific “on-target” activity of bortezomib by independent approaches including, but not limited to, genetic manipulation of the target level (over- and underexpressing strains) and by establishing a dynamic structure-activity relationship between ClpP1P2 and growth inhibition. Identifying an “on-target” compound is critical to optimize the efficacy of the compound without compromising its specificity. This work demonstrates the feasibility of target mechanism-based whole-cell screening methods, validates ClpP1P2 as a druggable target, and delivers a lead compound for tuberculosis therapy.https://journals.asm.org/doi/10.1128/mBio.00253-15 |
| spellingShingle | Wilfried Moreira Grace J. Y. Ngan Jian Liang Low Anders Poulsen Brian C. S. Chia Melgious J. Y. Ang Amelia Yap Justina Fulwood Umayal Lakshmanan Jolander Lim Audrey Y. T. Khoo Horst Flotow Jeffrey Hill Ravikiran M. Raju Eric J. Rubin Thomas Dick Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria mBio |
| title | Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria |
| title_full | Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria |
| title_fullStr | Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria |
| title_full_unstemmed | Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria |
| title_short | Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria |
| title_sort | target mechanism based whole cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria |
| url | https://journals.asm.org/doi/10.1128/mBio.00253-15 |
| work_keys_str_mv | AT wilfriedmoreira targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT gracejyngan targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT jianlianglow targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT anderspoulsen targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT briancschia targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT melgiousjyang targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT ameliayap targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT justinafulwood targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT umayallakshmanan targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT jolanderlim targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT audreyytkhoo targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT horstflotow targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT jeffreyhill targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT ravikiranmraju targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT ericjrubin targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria AT thomasdick targetmechanismbasedwholecellscreeningidentifiesbortezomibasaninhibitorofcaseinolyticproteaseinmycobacteria |